EGFR and non-small cell lung carcinoma: Thus, the universe of single-agent treatment of advanced EGFR-mutant NSCLC with EGFR-TKIs, already to be considered successful compared with the outcomes of non-oncogene-addicted NSCLC, had achieved the utmost level in terms of efficacy and safety profile with the third-generation EGFR TKI osimertinib.